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Abstract
Background: The most commonly applied treatment for acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) is a 5-day course of high-dose systemic corticosteroids. However, this treatment has not been
shown to reduce mortality and can potentially have serious side effects.
Recent research has shown that, presumably, only a subgroup of COPD patients identifieable by blood eosinophil count
benefit from a rescue course of prednisolone. By applying a biomarker-guided strategy, the aim of this study is to determine
whether it is possible to reduce the use of systemic corticosteroids in AECOPD without influencing the outcome.
Methods: This is an ongoing prospective multicenter randomized controlled open label trial comprising 320 patients with
AECOPD recruited from four hospitals in Denmark. The patients are randomized 1:1 to either standard care or eosinophil-
guided corticosteroid-sparing therapy where prednisolone is not administered if the daily blood sampling reveals an eosinophil
level below 0.3 × 109 cells/L. The primary endpoint is length of hospital stay within 14 days after recruitment. The secondary
endpoints are treatment failure, 30-day mortality rate, COPD related re-admission rate, change in FEV1, and a number of
adverse effect measures obtained within 3 months after the index hospitalisation date related to corticosteroid usage.
Discussion: This will be a very large RCT providing knowledge about the effectiveness of individualized biomarker-guided
corticosteroid therapy in hospitalised patients with AECOPD.
Trial registration: Clinicaltrials.gov, NCT02857842, 02-august-2016. Clinicaltrialregister.eu: Classification Code: 10,010,953,
02-marts-2016.
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Background
Acute exacerbation of chronic obstructive pulmonary
disease (AECOPD) often leads to hospitalization and is
associated with a high mortality rate. AECOPD episodes
lead to accelerated decline in lung function and have
negative impact on physical activity and quality of life.
Furthermore, AECOPD implies high socioeconomic
costs [1]. For decades, systemic corticosteroids have
been a cornerstone in management of moderate to se-
vere AECOPD. However, the optimal approach as
regards the duration of treatment is unknown [2]. The
REDUCE study concluded that a 5-day course of sys-
temic corticosteroids is noninferior to 14-days of treat-
ment [3]. Based on this, the recent GOLD strategy
document recommends five to seven days of systemic
corticosteroid treatment for patients with AECOPD [4].
Previous research
A more recent Cohrane review (13 studies contributed
data, n = 1620) regarding AECOPD patients has shown
that systemic corticosteroids (compared to placebo) re-
duce the risk of treatment failure (number needed to
treat (NNT) = 9; 95% confidence interval (CI) 7 to 14).
Treatment failure was defined as patients who within
30 days required hospitalization or emergency room
visits or patients requiring add-on pharmacological
maintenance therapy. The risk of recurrence of
AECOPD was also reduced within the first month (haz-
ard ratio (HR) 0.78; 95% CI 0.63 to 0.97), whereas no
difference in AECOPD recurrence was observed during
the following 3 months [3].
Lung function measured up to 72 h after first adminis-
tration of systemic corticosteroids showed significant
improvement in forced expiratory volume in 1 s (FEV1)
in the corticosteroid group (mean difference (MD)
140 mL; 95% CI 90 to 200), whereas this difference was
not observed at later time-points. No difference was ob-
served in mortality (odds ratio (OR) 1.0; 95% CI 0.60
to1.66). The total length of hospital stay (LOS) was
shorter in the corticosteroid-treated group (MD
−1.22 days; 95% CI -2.3 to −0.2), whereas there was no
difference in the LOS in intensive care unit. The risk of
steroid induced side effects was, as expected, increased
(OR 2.33; 95% CI 1.59 to 3.43) in the corticosteroid-
treated group compared with the control group; number
needed to harm (NNH) = 6; 95% CI 4 to 10). Meanwhile,
the proportion of side effects in the corticosteroid group
(48.1%) was considerably higher than the control group
(28.5%). The risk of hyperglycemia was increased (OR
2.79; 95% CI 1.86 to 4.19) and the absolute risk was
28.2% [3]. Others have identified serious psychiatric side
effects (depression, mood changes, psychosis) and ser-
ious somatic side effects such as hypertension, ulcers,
secondary adrenal insufficiency, diabetes, osteoporosis
and increased risk of bone fractures in patients exposed
to long-term systemic corticosteroids [5–7].
Earlier, the inflammatory process in patients with
AECOPD was believed to be homogeneous, primarily
neutrophilic. However, recent studies have shown that
both inflammation [8, 9] and ethiology [10–12] are het-
erogeneous. It has been demonstrated that a subgroup
of patients with AECOPD have eosinophilic inflamma-
tion [13]. Specific attention on biological clusters and
biomarkers of these have resulted in an increased under-
standing of the differentiated inflammatory mechanisms
that exist in AECOPD [14]. Examinations of sputum
from the airways in smokers have increased this under-
standing further [15].
A small randomized study (n = 109) of COPD patients
with moderate exacerbations has indicated that blood
eosinophil-guided corticosteroid treatment might reduce
the use of systemic corticosteroids in exacerbations by
49% without simultaniously worsening of symptoms and
increasing risk of treatment failure compared with
standard care [16]. Furthermore, patients with initial low
eosinophil count more often experienced treatment fail-
ure if they had received corticosteroid therapy rather
than if they had not (15% treatment failure in prednisol-
one group, 2% treatment failure in corticosteroid-saving
group, p = 0.04). However, the study had no impact on
current recommendations due to the limited sample
size. Larger cohort studies documented that diagnosed
COPD patients with daily symptoms have more than 3-
fold increased risk for AECOPD if they have an eosino-
phil count ≥0.34 × 109 cells/L [17].
So, the question that remains to be answered based on
the currently available studies is whether the clinical ef-
fects of systemic corticosteroid treatment in hospitalised
patients with AECOPD can be achieved via a more tar-
geted and individualized eosinophil-guided treatment ra-
ther than the current “one-size fits all” treatment. To
our knowledge, no randomized clinical trials have yet ex-
amined this field. This study will address this important
question. The aim is to determine whether it is possible
to reduce the use of systemic corticosteroids in
AECOPD without influencing the outcome by applying
a biomarker-guided strategy. Additionally, the study will
explore whether this strategy reduces some of the most
frequent side effects that occur with the current stand-
ard treatment.
Methods
Objective
The overall objective is to determine whether a prednis-
olone regimen with lower accumulated doses in hospita-
lised patients with AECOPD have noninferior clinical
outcome than when applying standard care (SC). Based
on a sufficiently sized (powered) clinical study, the aim
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is to determine if there is no relevant increase in LOS
for AECOPD patients receiving eosinophil guided
prednisolone-sparing therapy compared to SC. The pri-
mary endpoint of this analysis is LOS defined as the time
from hospital admission to hospital discharge within
14 days after recruitment. The secondary objective is to
determine if the clinical outcome for patients receiving
eosinophil guided corticosteroid-sparing therapy will not
be less favourable compared to SC. The following end-
points will be included when assessing the clinical out-
come: 30-day mortality rate, treatment failure, COPD
related re-admission rate, changes in FEV1, changes in
health-related quality-of-life measured by COPD Assess-
ment Test (CAT), changes in level of dyspnoea using the
modified Medical Research Council (mMRC) Dyspnoea
Scale, cumulative systemic corticosteroid dose, the
period between index AECOPD and the next AECOPD
and a number of adverse effect measures between index
hospitalization and 3 month follow-up. The adverse ef-
fect measures include hyperglycemia, osteopenia (Bone
Turnover Markers: C-terminal telopeptide of type 1 col-
lagen (CTX) and procollagen type 1 N propeptide
(P1NP)), osteoporotic fractures, dyspepsia or ulcer com-
plications (gastrointestinal bleeding), onset of diabetes
mellitus (defined as HbA1c ≥ 48 mmol/mol) or worsen-
ing of diabetes mellitus (defined as initiation/intensifica-
tion of anti-diabetic treatment), increase in Body Mass
Index and new infections treated with antibiotics since
study entry.
Study design, randomization and intervention
The study will be conducted as a prospective, multicen-
ter, randomized, controlled, open-label study in hospita-
lised patients with AECOPD. In total, 320 patients are
expected to be included in the project within 24 months.
Patients will be randomly assigned in a 1:1 fashion to ei-
ther an intervention group where guidance of prednisol-
one treatment is based on daily eosinophil count
(“eosinophil-guided corticosteroid-sparing therapy”) or a
standard group in which guidance of prednisolone is
based on an existing guideline, see below. Pre-stratified
block randomization with blocks of varying (and
blinded) size will be applied to ensure equal distribution
of patients on site (four different pulmonary depart-
ments in Denmark) and age (above or below 70 years of
age). The study was monitored according to Good Clin-
ical Practice (GCP) by the GCP unit at Bispebjerg Uni-
versity Hospital, Copenhagen, Denmark.
Patients will be randomized to one of the two treat-
ment arms:
a) Standard Care (SC) group: Intravenous
methylprednisolone 80 mg on the first day followed
by 37.5 mg of prednisolone tablets daily for 4 days.
b) Intervention group: Intravenous methylprednisolone
80 mg, followed by prednisolone tablet 37.5 mg daily
(maximum of 4 days in all) on days where the blood
eosinophil count is ≥0.3 × 109 cells/L. On days with
eosinophil count <0.3 × 109 cells/L systemic
corticosteroid treatment will not be administered.
If a patient is discharged during the treatment period,
a treatment based on the last measured eosinophil count
will be prescribed for the remaining days within the
5 day-period.
Selection of participants All consecutive patients ad-
mitted with AECOPD in participating centres will be
considered for study enrolment (Fig. 1). Fulfilling the in-
clusion and exclusion criteria, patients will be invited to
participate in the project. The aim is to enroll a sample
representative of hospitalized patients with AECOPD in
Denmark. Subjects on chronic systemic corticosteroids
will be eligible for inclusion if they are receiving systemic
corticosteroids corresponding to 5–10 mg daily. Patients
receiving non-invasive ventilation (Continuous Positive
Airway Pressure/Bilevel Positive airway pressure) were
only recruited if they were admitted at one of the four
recruiting departments.
Inclusion criteria
 Hospitalized patients with AECOPD within 24 h
after admission
 Age ≥ 40 years
 Spirometry-verified COPD (defined as
postbronchodilator FEV1/FVC ≤ 0.70)
Exclusion criteria
 Self-reported physician diagnosed asthma
 Life expectancy less than 30 days
 Severe COPD exacerbation requiring invasive
ventilation or admission to ICU
 Allergy to systemic corticosteroids
 Severe mental illness which is not controlled by
medication
 People who are detained under the act on the use of
coercion in psychiatry
 Severe language difficulties or inability to provide
written informed consent
 Pregnancy and lactation
 Systemic fungal infections
Measurements
All outcome measures will be recorded at baseline and
at the one and three month follow up visits (Table 1).
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On the baseline visit (during hospitalization), the follow-
ing variables will be noted: sociodemographic data (e.g.
sex, age, height, weight, ethnicity), smoking history,
pack-years, co-morbidities (including the presence of
diabetes, heart failure, ischemic heart disease, atrial
fibrillation, essential hypertension, hypercholesterol-
emia), employment status, support with activities of daily
living at home, clinical symptoms (increased dyspnea,
increased sputum volume, and increased sputum puru-
lence (Anthonisen criteria), increased cough), disease
symptoms duration, body mass index (kg/m2), number
of exacerbations in the past, atopy status, mean cumula-
tive systemic corticosteroid dose (mg) 4 weeks before
study entry, use of oxygen therapy, use of noninvasive
mechanical ventilation, vital signs, adverse events to
systemic corticosteroids, medication adherence by day 5,
arterial blood gases and Ca2+, blood samples, findings
from Chest X-ray and spirometry will be collected and
stored on Case Report Forms in pseudoanonymised
format at the treatment site (Table 1). Furthermore,
patients will be requested to complete the CAT and
mMRC Dyspnoea Scale. Follow-up visits will be con-
ducted one and three months after discharge. If the
patient does not attend the visit, the patient will be
contacted for a new follow-up or - if not able to meet
for an appointment at the hospital - a home visit by a
doctor assigned to the project. At the one month and
the three month follow up visits the following data will
be assessed: BMI, HbA1c (only at the one month follow-
up), spirometry values, CAT score, mMRC, CTX, P1NP,
PTH (only at the three month follow-up), D-vitamin
status (only at the three month follow-up), cumulative
systemic corticosteroid dose, the period between index
AECOPD and the next AECOPD, COPD related re-
admission rate, dyspepsia or ulcer complications (gastro-
intestinal bleeding) and new infections treated with anti-
biotics since study entry.
Collection of data and storage will comply with Good
Clinical Practice guidelines as defined by the Inter-
national Conference on Harmonisation guidelines [18].
Analysis of anonymised data will be conducted by the
Table 1 Data collected at baseline and follow-up visits
Data collected Study period
Baseline 1-month 3-month
Demographics X
Daily blood glucose
measurements
X
Daily leukocyte differential
counta
X
Arterial blood gases and
Chest X-ray
X
Testing for diabetes (HbA1c) X X
Spirometry X (day 1 + day 3) X X
Height measurement &
vital signs
X
Weight measurement X X X
Vitamin D and PTH levels X X
COPD Assessment Test (CAT) X X X
Medical Research Council
Dyspnoea Scale
X X X
Bone Turnover Markers
(CTX, P1NP)
X X X
Questionnaire on general
health condition
X X
Pregnancy test X
aCompleted by patients in the intervention group only
Fig. 1 Flowchart of patients through the study
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principal investigator with assistance from site investiga-
tors and supervisors.
Medication adherence
All patients discharged during the treatment period
(< 5 days) will be contacted in order to confirm whether
the prescribed medication has been taken. This is to control
for adherence with prescribed medication and to keep an
accurate record of doses of medication for each patient.
Withdrawal of study
In general, no subject should be removed from the study
for a protocol violation prior to confirmation by the coord-
inating investigator. A patient is only to be withdrawn from
the study if the participant explicitly asks for withdrawal.
Size of the study population and statistical considerations
Data will be analysed using intention-to-treat (ITT)
principles, including all the data available regardless of
whether the intervention is completed. The aim of the
ITT analysis is also to provide unbiased comparisons
among groups and avoid the effects of dropout and han-
dle patients who deviates from the protocol, e.g. intu-
bated patients during their hospitalization.
Patients in SC will be compared to patients with eosino-
phil guided prednisolone sparing therapy (Intervention
group). The mean LOS (μ = 8) and standard deviation
(σ = 3.81 days) after a hospitalization for AECOPD is esti-
mated based on previous studies comparing systemic corti-
costeroids versus placebo [3, 19]. A two-sided 95%-
confidence interval will be computed for the difference in
LOS in the intervention group minus standard care group.
We will accept a null hypothesis if the LOS in the interven-
tion group does not exceed 1.2 days of the average LOS in
the SC arm. The probability that the study will detect a
treatment difference is 80% at a two-sided 5% significance
level. This provides a sample size of 320 subjects. Sample-
size calculation has been performed by using SAS software
(version 9.4).
The results are expressed in mean (days) and SD if
data is normally distributed, or as median (IQR). Data
will be analysed using SAS software.
Trial Steering Committee & Data Safety Monitoring Board
A Trial Steering Committee has been established. We
will meet twice a year with the Committee to advice the
research team. Chair: MD, PhD Jens Ulrik Stæhr Jensen
A Data Safety Monitoring Board are in place to closely
and independently monitor the safety of the CORTICO-
COP study.
Publication of test results
The test results will be published regardless of whether
they are positive, negative or in-conclusive. Publication in
international peer-reviewed scientific journals is planned
accompanied by parallel publications in Danish Medical
Journal. We aim to publish in high impact scientific jour-
nals. Results that cannot be published in peer-reviewed
journals will be published on www.coptrin.eu and con-
gresses in the form of posters and oral presentations.
Discussion
COPD is a heterogeneous disease and is, by that, also as-
sociated with different responses to systemic corticoste-
roids for acute worsening of the disease. Although
systemic corticosteroids improve some clinical outcomes
in AECOPD - such as LOS, FEV1 on day 3, treatment
failure and re-exacerbation rate the first month - the
magnitude of benefit is small and probably restricted to
subgroups of patients [3].
The novel aspect of this study is to investigate non-
inferiority of eosinophilic guided corticosteroid-sparing ther-
apy against the current standardized treatment of 5 days to
all AECOPD patients. The study investigates whether the
accumulated dose of systemic corticosteroid treatment dur-
ing admissions for AECOPD can be reduced, including the
presumed side effects, while simultaneously attaining the
optimal treatment effect. Studies have shown that systemic
corticosteroids improve outcome in exacerbations associated
with either serum eosinophil counts equal to or above 2%
[16] or eosinophil counts equal to or above 0.34 109 cells/L
[20]. However, on the other hand, this therapy might be
detrimental in those with lower eosinophil counts [16]. A
recent retrospective study has found that blood eosinophil-
positive (eosinophilia ≥2%) severe AECOPD require a lower
daily dose of systemic corticosteroids during hospitalization
compared to blood eosinophil-negative (eosinophilia <2%)
AECOPD. Thereby, the study concludes that the group with
blood eosinophil-positive severe AECOPD respond better to
systemic corticosteroids. Moreover, the former group had a
shorter LOS (geometric mean 8.9 ± 1.5 versus 11.3 ± 1.5 days,
respectively; p = 0.028) [21]. The result was supported by
another sub-group analysis within a large randomized clinical
trial which found shorter LOS in the group with eosinophilic
(blood eosinophil count ≥200 cells/μL and/or ≥2% of the
total leukocyte count) associated exacerbations (mean
(range) 5.0 (1–19) vs. 6.5 (1–33), p = 0.015) following treat-
ment with systemic corticosteroids [22].
Blood eosinophil count appears to be a promising bio-
marker that can be applied in the clinic to predict treat-
ment response in patients with AECOPD. This could be
beneficial by improving clinical outcome, decrease side ef-
fects and reduce any overuse of systemic corticosteroids
[21]. The study will contribute with data to make clinical
decisions on how to rationally individualize prednisolone
treatment in hospitalized patients with AECOPD with the
aim of optimizing treatment effect and reducing side
effects.
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Trial status
Patient recruitment commenced in August 2016 and is
ongoing.
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